<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34953656</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0828</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>97</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of internal medicine</Title>
          <ISOAbbreviation>Eur J Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Interstitial pneumonia with autoimmune features: Evaluation of connective tissue disease incidence during follow-up.</ArticleTitle>
        <Pagination>
          <StartPage>62</StartPage>
          <EndPage>68</EndPage>
          <MedlinePgn>62-68</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejim.2021.12.021</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0953-6205(21)00432-5</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Among interstitial pneumonia with autoimmune features (IPAF) patients, identifying those at risk to develop a connective tissue disease (CTD) during the disease course is a key issue. The aim of this study was to evaluate the incidence of definite CTD diagnosis in IPAF patients during follow-up.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We performed a multicentric cohort study of interstitial lung disease (ILD) from 2010 to 2017 in pneumology and immunology departments of tertiary care centers. Patients with a known cause of ILD (including established CTD) at diagnosis were excluded. Among patients with idiopathic ILD and at least three years of follow-up, two groups (IPAF and non-IPAF) were retrospectively analyzed at time of diagnosis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 249 patients with ILD were enrolled, including 70 IPAF and 179 non-IPAF patients. After a mean follow-up time of 77 ± 44 months, 18/70 IPAF patients (26%) had a CTD diagnosis - 9 antisynthetase syndrome, 8 systemic sclerosis and 1 overlap myositis - compared with 4/179 non-IPAF patients (2%). IPAF patients were at higher risk of CTD occurrence at 3 years of follow-up compared to non-IPAF patients (HR 10.1, 95% CI 3.1-33.1, p &lt; 0. 01). IPAF patients progressing to CTD tended to be younger, more often female and have more frequently puffy fingers, capillaroscopy abnormalities and antisynthetase antibodies at diagnosis.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found that a significant proportion of IPAF patients had associated CTD diagnosis during follow-up. Prospective studies are needed to confirm baseline predictive factors of CTD occurrence in IPAF patients.</AbstractText>
          <CopyrightInformation>Copyright © 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Decker</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine and Clinical Immunology, Center de Compétence des Maladies Autoimmunes Systémiques Rares, CHU Nancy, University of Lorraine, 5 Rue du Morvan, Vandoeuvre-lès-Nancy 54500, France. Electronic address: p.decker@chru-nancy.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sobanski</LastName>
            <ForeName>Vincent</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine and Clinical Immunology, Center de Référence des maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU Lille, University of Lille, Lille F-59000, France; University of Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille F-59000, France; INSERM, Lille F-59000, France; Institut Universitaire de France (IUF), France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moulinet</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine and Clinical Immunology, Center de Compétence des Maladies Autoimmunes Systémiques Rares, CHU Nancy, University of Lorraine, 5 Rue du Morvan, Vandoeuvre-lès-Nancy 54500, France; UMR 7365, IMoPA, University of Lorraine, CNRS, Nancy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Launay</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine and Clinical Immunology, Center de Référence des maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU Lille, University of Lille, Lille F-59000, France; University of Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille F-59000, France; INSERM, Lille F-59000, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hachulla</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine and Clinical Immunology, Center de Référence des maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU Lille, University of Lille, Lille F-59000, France; University of Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille F-59000, France; INSERM, Lille F-59000, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Valentin</LastName>
            <ForeName>Victor</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pneumology and Immuno-Allergology, Center de Référence Constitutif Pour les Maladies Pulmonaires Rares, CHU Lille, University of Lille, Lille F-59000, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Godbert</LastName>
            <ForeName>Benoit</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pneumology, Metz Private Hospital, Metz, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Revuz</LastName>
            <ForeName>Sabine</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Metz Private Hospital, Metz, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guillaumot</LastName>
            <ForeName>Anne</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pneumology, CHU Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gomez</LastName>
            <ForeName>Emmanuel</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pneumology, CHU Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chabot</LastName>
            <ForeName>François</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pneumology, CHU Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wémeau</LastName>
            <ForeName>Lidwine</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pneumology and Immuno-Allergology, Center de Référence Constitutif Pour les Maladies Pulmonaires Rares, CHU Lille, University of Lille, Lille F-59000, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jaussaud</LastName>
            <ForeName>Roland</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine and Clinical Immunology, Center de Compétence des Maladies Autoimmunes Systémiques Rares, CHU Nancy, University of Lorraine, 5 Rue du Morvan, Vandoeuvre-lès-Nancy 54500, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Eur J Intern Med</MedlineTA>
        <NlmUniqueID>9003220</NlmUniqueID>
        <ISSNLinking>0953-6205</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003240" MajorTopicYN="Y">Connective Tissue Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antisynthetase syndrome</Keyword>
        <Keyword MajorTopicYN="N">Connective tissue disease</Keyword>
        <Keyword MajorTopicYN="N">Interstitial lung disease</Keyword>
        <Keyword MajorTopicYN="N">Interstitial pneumonia with autoimmune features</Keyword>
        <Keyword MajorTopicYN="N">Systemic sclerosis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>26</Day>
          <Hour>20</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34953656</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejim.2021.12.021</ArticleId>
        <ArticleId IdType="pii">S0953-6205(21)00432-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
